Background:

Cefepime Dihydrochloride Monohydrate is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria[1].

Cefepime is an extended-spectrum parenteral cephalosporin antibiotic active in vitro against a broad spectrum of gram-positive and gram-negative aerobic bacteria. Cefepime has a decreased propensity to induce beta-lactamases compared with other beta-lactam antibiotics[1].

Cefepime has a pharmacokinetic disposition similar to that of other renally eliminated cephalosporins, with a half-life of approximately 2 hours. Cefepime has demonstrated clinical efficacy against a variety of infections, including urinary tract infections, pneumonia, and skin and skin structure infections. Cefepime is generally well tolerated[2].

参考文献:
[1]. Neu, H.C., Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med, 1996. 100(6A): p. 68S-75S.
[2]. Wynd, M.A. and J.A. Paladino, Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother, 1996. 30(12): p. 1414-24.